Factive Superiority Trials Needed to Evaluate Efficacy In Acute Sinusitis, FDA Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel votes 11-2 that Oscient has not demonstrated gemifloxacin is safe and efficacious in treatment of acute bacterial sinusitis.
You may also be interested in...
BrainStorm’s ALS Treatment NurOwn, Filed Over Protest, Will Get US FDA Panel Review
A November 2022 refuse-to-file letter cited clinical and statistical issues for the stem cell therapy, which failed its Phase III clinical efficacy endpoint. However, BrainStorm has consistently asserted that NurOwn demonstrated benefit in patients with less advanced disease at baseline, and it is encouraged by regulatory flexibility FDA recently has shown for the neurodegenerative disease.
Oscient’s Factive Clears FDA For Five-Day Community Acquired Pneumonia Indication
Antibiotic is the only fluoroquinolone approved in the U.S. for five-day treatment of both CAP and AECB.
Oscient’s Factive Clears FDA For Five-Day Community Acquired Pneumonia Indication
Antibiotic is the only fluoroquinolone approved in the U.S. for five-day treatment of both CAP and AECB.